Ubiquitin C-terminal hydrolase 1 (UCHL1) is also known as ubiquitin carboxyl esterase L1, ubiquitin thiolesterase, neuron-specific protein PGP9.5 and Park5. It was originally identified as a major component of the neuronal cytoplasm from 2-dimensional gel analysis of brain tissues, and was given the name PGP9.5 (1). It was later found that ubiquitin C-terminal hydrolase enzyme activity was associated with the PGP9.5 protein (2). The ubiquitin C-terminal hydrolases cleave ubiquitin from other molecules. Regulation of the ubiquitin pathway is very important and many disease states are associated with defects in this pathway. Genetic knockout of UCHL1 in mice results in a motor neuron degeneration similar to the spontaneous gracile axonal dystrophy (gad) mutant mice (3). Point mutations in the UCHL1 gene are associated with some forms of human Parkinson's disease (4). Since UCHL1 is heavily expressed in neurons, it is released in large amounts following injury or degeneration, so the detection of UCHL1 in CSF and other bodily fluids can be used as a biomarker.
应用类型
WB, IF
免疫原
Recombinant full length human UCHL1 purified from E. coli.
来源宿主
Chicken
反应性
该Anti-Ubiquitin C Terminal Hydrolase 1 (UCHL1)的反应性请参考该产品的说明书
保存建议
Store at -20C in undiluted aliquots; stable for at least 1 year. Avoid freeze/thaw cycles.
其他
Aviva Systems Biology总部位于加利福尼亚州圣迭戈，在中国北京设有办公室，专注于为研究需求提供多克隆和单克隆抗体、ELISA试剂盒、蛋白质和定制服务。Aviva Systems Biology生产了24,000种经过验证的多克隆抗体，并提供近20,000种ELISA试剂盒，定制实验室服务包括蛋白表达和纯化、抗体开发，以及ELISA的开发、验证和生产。Aviva Systems Biology为与独特物种和靶标相关的研究提供独特工具，研究领域包括转录因子、癌症、心血管、细胞生物学、DNA损伤和修复、表观遗传学、信号转导、细胞分化、干细胞生物学等等。
